Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis
Paul G. Richardson(Harvard University), Joan Bladé(Hospital Clínic de Barcelona), Olof Harlin(Oncopeptides (Sweden)), Alessandra Larocca(Cornell University), María‐Victoria Mateos(Hospital Clínico San Carlos), Adrían Alegre(Hospital Universitario de La Princesa), Johan Harmenberg(Oncopeptides (Sweden)), Noemí Puig(Instituto de Investigación Biomédica de Salamanca), Xavier Leleu(Inserm), Omar Nadeem(Harvard University), Albert Oriol(Institut Català d'Oncologia), Anastasios Raptis(University of Pittsburgh), Elena Zamagni(Istituti di Ricovero e Cura a Carattere Scientifico), Cyrille Touzeau(Centre National de la Recherche Scientifique), Hani Hassoun(Memorial Sloan Kettering Cancer Center), Michèle Cavo(Unknown), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Agner Paner(Rush University Medical Center), Marcus Thuresson(Statisticon (Sweden)), Amitabha Mazumder(NYU Langone Health), Christopher Maisel(Baylor Medical Center at Garland), John W. Hiemenz(University of Florida), Maxim Norkin(Centre Hospitalier Universitaire Vaudois)
Cited by 0
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k